LOTIS-9: what clinicians are saying
loncastuximab tesirine plus rituximab in previously untreated unfit/frail diffuse large B-cell lymphoma · NCT05144009 ↗ · Phase 2 · ADC Therapeutics S.A.
One speaker reads LOTIS-9 as a warning that avoiding chemotherapy does not remove toxicity, citing pulmonary deaths while questioning their reported attribution to comorbidities rather than drug effects. Their concern turns on cardiopulmonary reserve that functional frailty scores may not capture. Their comparison with R-mini-CHOP acknowledges different populations, leaving relative benefit unresolved. Another speaker calls for frailty-specific trials powered to assess benefit and toxicity; the discussion does not establish that treatment caused the deaths.
Created with AI · how we check it
- edition 1
- commentary checked Nov 22, 2026
- 49 verified statements
8 findings, and what sits behind each
01. LOTIS-9: speakers question AE attribution; one relays trial-only advice
No named clinician · accounts and unnamed speakers · 11 statements from 2 speakers in 5 sources · 5 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Secondary endpoints, Population and setting, Design and conduct, Primary endpoint: CR Rate.
02. Frailty and chemo-free care: why a speaker still stresses supportive care
No named clinician · accounts and unnamed speakers · 3 statements from 1 speaker in 1 source · 1 passage
Limitations recorded: 2.
Draws on: Safety and tolerability, Population and setting, Design and conduct.
03. LOTIS-9 CRs: a speaker questions value vs R-mini-CHOP despite differing populations
No named clinician · accounts and unnamed speakers · 6 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 3.
Draws on: Primary endpoint: CR Rate, Safety and tolerability, Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment, Secondary endpoints, The comparison, Design and conduct.
04. LOTIS-9: speakers welcome testing; a clinician ties an RCT to durable responses
1 of the report's 2 cited clinicians · 10 statements from 2 speakers in 4 sources, 3 of them podcasts or videos · 4 passages
Limitations recorded: 3.
Draws on: Population and setting, The comparison, Design and conduct, Secondary endpoints.
05. Older/unfit frontline DLBCL: a speaker highlights activity, not proof of superiority
No named clinician · accounts and unnamed speakers · 6 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 3.
Draws on: The comparison, Secondary endpoints, Safety and tolerability, Primary endpoint: CR Rate, Population and setting.
Beyond the trial population
06. Loncastuximab Tesirine: what speakers say
1 of the report's 2 cited clinicians · 5 statements from 3 speakers in 2 sources · 4 passages
Limitations recorded: 3.
07. Frailty trials: why a speaker seeks power for both efficacy and toxicity
No named clinician · accounts and unnamed speakers · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 2.
08. Contemporary combinations: why a speaker sees possible future standards
No named clinician · accounts and unnamed speakers · 1 statement in 1 source, a podcast or video · 2 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 8
No named clinician · accounts and unnamed speakers
LOTIS-9: speakers question AE attribution; one relays trial-only advice
11 statements from 2 speakers in 5 sources
2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “one relays trial-only advice”
- 11
- statements
- 5
- passages
- 5
- sources
- 2
- speakers
What the statements areViews 4Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 7Statement-to-passage links (a passage can back several statements)Supporting a statement 11Giving context 0Recorded with the findingLimitations: 3
4 posts and articles · 1 publication
Draws on: Safety and tolerability, Secondary endpoints, Population and setting, Design and conduct, Primary endpoint: CR Rate.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
3 of the 8 findings and 6 of the 49 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (6)
AE, adverse event; CR, complete response; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; RCT, randomized controlled trial.
The full LOTIS-9 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say would clarify whether pulmonary deaths in LOTIS-9 reflected comorbidities alone or also toxicity from loncastuximab tesirine plus rituximab as chemotherapy replacement in previously untreated unfit or frail DLBCL?
From findings F1 (11 statements from 2 speakers in 5 sources) and F4 (10 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 46commentary sources screened
- 13sources cited by verified statements
- 7named in screened sources
- 7speakers cited in the report
- 6cited speakers with a verified identity
2 cited clinicians, speakers with a confirmed clinical role, of them 2 physicians. By role and specialty:
- 1 physician, specialty not confirmed
- 1 physician, Medical oncology
Also in the sources: 1 organizational or shared account, not counted as people.
- 49verified statements, each linked to its source
- 11of them from speakers with a confirmed clinical role
- 8findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 49 | Paid |
| Who said each statement: the cited speakers | 7 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 2 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 6 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 13 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
12 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: CR Rate | 4 | 3 |
| Primary endpoint: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment | 1 | 1 |
| Secondary endpoints | 7 | 5 |
| Population and setting | 15 | 7 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 5 |
| Safety and tolerability | 14 | 5 |
| Design and conduct | 9 | 5 |
| Off-trial boundaries and transparent reporting | 3 | 2 |
| Organ reserve and supportive-care requirements | 3 | 1 |
| Treatment burden and patient-centered selection across alternatives | 5 | 1 |
| Broader drug adoption and accelerated-approval confidence | 4 | 2 |
| Long-term expectations for contemporary combinations | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
49 verified statements from 13 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 10 statements · 20% | ||||
| YouTube | 9 | 3 | 3 | |
| Podcasts | 1 | 1 | 1 | |
| Posts · 26 statements · 53% | ||||
| X threads | 15 | 5 | 41 | |
| LinkedIn posts | 11 | 1 | 1 | |
| Primary sources · 13 statements · 27%cited for context, not screened | ||||
| Registry | 9 | 2 | — | |
| Publications | 4 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 31 / quarter
- Screened window
- Jul 6, 2022 → Oct 28, 2026
- Cited window
- Jul 6, 2022 → Oct 28, 2026
- Retrieved
- Nov 22, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
- Registry
- NCT05144009
- Study IDs
- ADCT-402-203 · 2021-005312-57 · 2022-501601-12-00
- Sponsor
- ADC Therapeutics S.A.
- Design
- Phase 2 · Interventional, non randomized, sequential
- Status
- Terminated
- Enrollment
- 41 actual
- Registered
- 2021-12-03
- Start
- 2022-06-21 actual
- Primary completion
- 2024-01-22 actual
- Primary endpoints
- CR Rate
- Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment
- Interventions
- 2 registered
More on: Diffuse large B-cell lymphoma, loncastuximab tesirine, rituximab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a remark on trial discontinuation in previously untreated unfit or frail diffuse large B-cell lymphoma; a view on frontline polatuzumab-containing treatment, its approval basis, comparative efficacy, and follow-up limitations; a view on pretreatment assessment, treatment urgency and systemic versus local therapy in newly diagnosed diffuse large B-cell lymphoma.
- 3 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 39 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 14 known gaps +Fewer −
- Further source limits: 10 sources about other trials or topics are not included.
- The sources reviewed for this edition are a selective set of public discussions, not a representative sample of HCP opinion. Multiple sources or posts must not be interpreted as multiple independent clinicians.
- Discussion that did not name LOTIS-9 or used different wording may be missing. Some relevant podcast passages, including discussion of a frontline polatuzumab-containing regimen, were not fully assessed.
- Not all podcast statements can be assigned to named participants. The long-term treatment-landscape expectation therefore remains attributed to the episode rather than to a named speaker.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The July 2023 safety-hold discussion, 2022 rationale interviews and 2026 commentary describe different moments. Dates alone do not establish a change of mind or direct disagreement.
- ClinicalTrials.gov first posted results for the trial on 30 January 2025. The cited commentary spans 2022–2026 rather than wholly predating that posting.
- Cross-trial benchmarks and the shared-slide treatment snapshot do not establish comparative efficacy. The discrepant LOTIS-9 figures in the slide account and publication are not explained by the sources.
- Reported adverse events and clinical anecdotes do not establish treatment causality. The prophylaxis pattern does not establish prevention of fatal events, and the brief clinic reply does not identify an adverse-event type or patient population.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 22, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. LOTIS-9 (NCT05144009): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/lotis-9-nct05144009
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "LOTIS-9" (NCT05144009), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "lotis-9-nct05144009". If you cannot make requests, read https://www.erudio.com/reports/lotis-9-nct05144009.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05144009", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05144009 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/lotis-9-nct05144009.json
curl https://www.erudio.com/reports/lotis-9-nct05144009.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "lotis-9-nct05144009" })release a30a17c1d1b2c26501bb9a17adf1c8843a249bc383edd244bca6559d62f2f382
Questions
How much does the LOTIS-9 report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the LOTIS-9 report cover?
49 statements from 13 sources (1 podcast, 3 videos, 6 posts, 1 paper, 2 registry records), 11 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the LOTIS-9 report?
Its preview, yes: get_report_card({ "slug": "lotis-9-nct05144009" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the LOTIS-9 report?
Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.